Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A2B530 in Advanced Solid Tumors
NCT05736731Phase 2Active, not recruiting
- Sponsor
- A2 Biotherapeutics
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of A2B530 in colorectal cancer (CRC), pancreatic cancer (PC), non-small cell lung cancer (NSCLC), solid tumor, sponsored by A2 Biotherapeutics. Started Apr 2023; status: active, not recruiting.
02
Drugs
A2B530
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05736731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736731.